To further identify the effect of HSP27 on the chemoresistance of HER2+ BC, we analyzed 114 HER2+ BC patients from the publicly available Gene Expression Omnibus dataset (GSE50948; result from the Neoadjuvant Herceptin breast cancer trial), who received neoadjuvant doxorubicin/paclitaxel and cyclophosphamide/methotrexate/fluorouracil with or without one year of TZMB. This evidence concerns the gene ERBB2 and breast cancer.